In a recent pilot study of eleven Group 1 PAH patients and eleven age and sex-matched controls, Banerjee and colleagues reported that circulating SCN5a SV mRNA levels were much higher in PAH patients, compared with controls. This evidence concerns the gene SCN5A and pulmonary arterial hypertension.